EP1372392A4 - Forme posologique orale contenant de la nicotine - Google Patents

Forme posologique orale contenant de la nicotine

Info

Publication number
EP1372392A4
EP1372392A4 EP02721544A EP02721544A EP1372392A4 EP 1372392 A4 EP1372392 A4 EP 1372392A4 EP 02721544 A EP02721544 A EP 02721544A EP 02721544 A EP02721544 A EP 02721544A EP 1372392 A4 EP1372392 A4 EP 1372392A4
Authority
EP
European Patent Office
Prior art keywords
nicotine
dosage form
oral dosage
containing oral
oral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02721544A
Other languages
German (de)
English (en)
Other versions
EP1372392A1 (fr
Inventor
John Liu
Stanley J Lech
Stuart Platcow
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline LLC
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of EP1372392A1 publication Critical patent/EP1372392A1/fr
Publication of EP1372392A4 publication Critical patent/EP1372392A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Addiction (AREA)
  • Neurosurgery (AREA)
  • Nutrition Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
EP02721544A 2001-03-26 2002-03-22 Forme posologique orale contenant de la nicotine Withdrawn EP1372392A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27860601P 2001-03-26 2001-03-26
US278606P 2001-03-26
PCT/US2002/008914 WO2002076211A1 (fr) 2001-03-26 2002-03-22 Forme posologique orale contenant de la nicotine

Publications (2)

Publication Number Publication Date
EP1372392A1 EP1372392A1 (fr) 2004-01-02
EP1372392A4 true EP1372392A4 (fr) 2004-06-23

Family

ID=23065632

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02721544A Withdrawn EP1372392A4 (fr) 2001-03-26 2002-03-22 Forme posologique orale contenant de la nicotine

Country Status (11)

Country Link
EP (1) EP1372392A4 (fr)
JP (1) JP2004525928A (fr)
CN (2) CN101301275A (fr)
AR (1) AR033444A1 (fr)
AU (1) AU2002252470B2 (fr)
BR (1) BR0208382A (fr)
CA (1) CA2440713A1 (fr)
MX (1) MXPA03008762A (fr)
NZ (1) NZ528167A (fr)
PL (1) PL364621A1 (fr)
WO (1) WO2002076211A1 (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040253307A1 (en) * 2003-02-04 2004-12-16 Brian Hague Sugar-free oral transmucosal solid dosage forms and uses thereof
IL155666A (en) 2003-04-29 2013-12-31 Neurim Pharma 1991 Insomnia treatment
US9119846B2 (en) 2003-04-29 2015-09-01 Neurim Pharmaceuticals (1991) Ltd. Method and composition for enhancing cognition in alzheimer's patients
AU2004259006B2 (en) * 2003-07-24 2010-10-07 Glaxosmithkline Llc Orally dissolving films
GB0320854D0 (en) 2003-09-05 2003-10-08 Arrow No 7 Ltd Buccal drug delivery
US8627828B2 (en) 2003-11-07 2014-01-14 U.S. Smokeless Tobacco Company Llc Tobacco compositions
AU2004289248B2 (en) 2003-11-07 2012-05-03 U.S. Smokeless Tobacco Company Llc Tobacco compositions
JP4964773B2 (ja) * 2004-08-11 2012-07-04 クラフト・フーヅ・グローバル・ブランズ・エルエルシー 感覚惹起剤組成物及びそれらの送達システム
JP5254616B2 (ja) 2004-09-13 2013-08-07 クロノ セラピューティクス、インコーポレイテッド 生物学的同調性（ｂｉｏｓｙｎｃｈｒｏｎｏｕｓ）経皮的薬物送達
US8252321B2 (en) 2004-09-13 2012-08-28 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
AU2007328373A1 (en) * 2006-12-01 2008-06-12 Cima Labs Inc. Oral transmucosal nicotine dosage form
GB2468424B (en) * 2007-04-02 2011-11-09 Parkinson S Inst Methods and compositions for reduction of side effects of therapeutic treatments
WO2008122049A2 (fr) * 2007-04-02 2008-10-09 Parkinson's Institute Procédés et compositions pour la réduction des effets secondaires des traitements thérapeutiques
DE102008012015A1 (de) 2008-03-01 2009-09-10 Südzucker AG Mannheim/Ochsenfurt Verbesserte Isomalt-haltige Komprimate und Verfahren zu ihrer Herstellung
MX2012009586A (es) * 2010-02-18 2012-09-12 Jatin Vasant Thakkar Patillas de gelatina blanda con nicotina.
US20110274628A1 (en) 2010-05-07 2011-11-10 Borschke August J Nicotine-containing pharmaceutical compositions
UA112974C2 (uk) 2010-09-16 2016-11-25 Джеі. Бі. Кемікалс Енд Фармасьютікалс Лімітид Нікотиновмісна композиція (варіанти)
CA2841785A1 (fr) 2011-07-06 2013-01-10 The Parkinson's Institute Compositions et methodes de traitement de symptomes chez des patients atteints de la maladie de parkinson
US9474303B2 (en) * 2011-09-22 2016-10-25 R.J. Reynolds Tobacco Company Translucent smokeless tobacco product
US9629392B2 (en) 2011-09-22 2017-04-25 R.J. Reynolds Tobacco Company Translucent smokeless tobacco product
US9084439B2 (en) 2011-09-22 2015-07-21 R.J. Reynolds Tobacco Company Translucent smokeless tobacco product
US20130078307A1 (en) 2011-09-22 2013-03-28 Niconovum Usa, Inc. Nicotine-containing pharmaceutical composition
US9907748B2 (en) 2011-10-21 2018-03-06 Niconovum Usa, Inc. Excipients for nicotine-containing therapeutic compositions
US9044035B2 (en) * 2012-04-17 2015-06-02 R.J. Reynolds Tobacco Company Remelted ingestible products
AR096223A1 (es) * 2013-05-10 2015-12-16 Glaxosmithkline Llc Pastilla de nicotina para administración oral
CN104132895B (zh) * 2014-07-08 2017-08-25 国家烟草质量监督检验中心 适用于连续流动法测定烟草及烟草制品中总植物碱的缓冲体系
EP3250258A4 (fr) 2015-01-28 2018-09-05 Chrono Therapeutics, Inc. Procédés et systèmes d'administration de médicament
AU2016228779A1 (en) 2015-03-12 2017-09-07 Chrono Therapeutics Inc. Craving input and support system
JP2020503950A (ja) 2017-01-06 2020-02-06 クロノ セラピューティクス インコーポレイテッドＣｈｒｏｎｏ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 経皮薬剤送達の装置及び方法
SE541358C2 (en) * 2017-05-30 2019-08-13 Enorama Pharma Ab Nicotine-containing chewing gum compositions
US11596779B2 (en) 2018-05-29 2023-03-07 Morningside Venture Investments Limited Drug delivery methods and systems
WO2021144367A1 (fr) * 2020-01-15 2021-07-22 Mcneil Ab Pastille
US20220313678A1 (en) * 2021-04-06 2022-10-06 Altria Client Services Llc Spray dried nicotine for inclusion in oral products

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5593684A (en) * 1993-08-04 1997-01-14 Pharmacia Ab Method and therapeutic system for smoking cessation
US5662920A (en) * 1993-07-26 1997-09-02 Pharmacia Ab Nicotine lozenge and therapeutic method for smoking cessation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9310412D0 (en) * 1993-05-20 1993-07-07 Danbiosyst Uk Nasal nicotine system
DE19536394A1 (de) * 1995-09-29 1997-04-03 Basf Ag Feste Arzneiformen, erhältlich durch Extrusion einer Isomalt enthaltenden Polymer-Wirkstoff-Schmelze
DE19639342C2 (de) * 1996-09-25 1998-07-16 Suedzucker Ag Kaugummi, enthaltend ein Süßungsmittel
US6322806B1 (en) * 1999-04-06 2001-11-27 Wm. Wrigley Jr. Company Over-coated chewing gum formulations including tableted center

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5662920A (en) * 1993-07-26 1997-09-02 Pharmacia Ab Nicotine lozenge and therapeutic method for smoking cessation
US5593684A (en) * 1993-08-04 1997-01-14 Pharmacia Ab Method and therapeutic system for smoking cessation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO02076211A1 *

Also Published As

Publication number Publication date
AU2002252470B2 (en) 2008-05-22
AR033444A1 (es) 2003-12-17
EP1372392A1 (fr) 2004-01-02
CA2440713A1 (fr) 2002-10-03
BR0208382A (pt) 2004-06-15
PL364621A1 (en) 2004-12-13
CN1553771A (zh) 2004-12-08
MXPA03008762A (es) 2004-02-18
CN101301275A (zh) 2008-11-12
NZ528167A (en) 2005-04-29
JP2004525928A (ja) 2004-08-26
WO2002076211A1 (fr) 2002-10-03

Similar Documents

Publication Publication Date Title
PL364621A1 (en) Nicotine-containing oral dosage form
EG23943A (en) Flash-melt oral dosage formulation
PL356358A1 (en) Solid dosage form of someticone for oral administration
PL367180A1 (en) Stabilized oral pharmaceutical composition
GB0117618D0 (en) Pharmaceutical dosage form
HUP0203204A3 (en) Oral dosage forms
EP1383518A4 (fr) Administration orale de macromolecules
IL154012A0 (en) Hydrogel-driven drug dosage form
PT1362582E (pt) Forma de dosagem sólida revestida
AU8616801A (en) Oral solid dose vaccine
PL365518A1 (en) Oral composition
GB0117619D0 (en) Pharmaceutical dosage form
HUP0400850A3 (en) Oral pharmaceutical compositions
IL166337A0 (en) Oral administration of calctionin
HUP0500638A2 (en) Flashmelt oral dosage formulation
GB2383989B (en) Improved oral medicine dispenser
HUP0401599A3 (en) Extended release oral dosage form
EP1429615A4 (fr) Vaccins par voie orale
EP1357898A4 (fr) Forme posologique orale a liberation regulee amelioree
EP1361866A4 (fr) Emulsions en formes posologiques solides pour l'administration orale
GB0014497D0 (en) Oral dosage form
PL373799A1 (en) Flashmelt oral dosage formulation
HK1047232A1 (zh) 口服劑型
PL341178A1 (en) Oral pharmaceutical dosage forms
GB9925069D0 (en) Oral dosage form

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030922

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

A4 Supplementary search report drawn up and despatched

Effective date: 20040507

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61K 31/465 B

Ipc: 7A 61K 9/20 A

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1061622

Country of ref document: HK

17Q First examination report despatched

Effective date: 20071108

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: GLAXOSMITHKLINE LLC

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1061622

Country of ref document: HK

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20101001